Crews Bank & Trust Purchases Shares of 935 argenx SE (NASDAQ:ARGX)

Crews Bank & Trust acquired a new stake in shares of argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 935 shares of the company's stock, valued at approximately $575,000.

Several other large investors have also modified their holdings of ARGX. Cromwell Holdings LLC grew its position in argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after purchasing an additional 66 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company's stock worth $94,000 after buying an additional 56 shares during the period. SG Americas Securities LLC grew its holdings in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after buying an additional 21 shares in the last quarter. Fulton Bank N.A. acquired a new position in argenx during the fourth quarter valued at $226,000. Finally, Blue Trust Inc. lifted its stake in argenx by 413.9% in the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company's stock worth $201,000 after acquiring an additional 298 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on ARGX. Deutsche Bank Aktiengesellschaft cut argenx from a "hold" rating to a "sell" rating in a research note on Friday, January 17th. Truist Financial reiterated a "buy" rating and issued a $700.00 price objective (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Baird R W lowered shares of argenx from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 1st. Raymond James reaffirmed a "strong-buy" rating and issued a $605.00 price target on shares of argenx in a research note on Thursday, October 10th. Finally, Oppenheimer reissued an "outperform" rating and set a $675.00 price objective (up previously from $646.00) on shares of argenx in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, argenx currently has an average rating of "Moderate Buy" and a consensus price target of $658.39.

argenx Trading Up 0.6 %

ARGX traded up $3.93 during trading on Monday, hitting $659.06. The stock had a trading volume of 186,173 shares, compared to its average volume of 278,836. The firm has a market cap of $40.04 billion, a PE ratio of -749.08 and a beta of 0.58. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21. The company has a 50 day simple moving average of $632.58 and a 200-day simple moving average of $571.05.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analysts' expectations of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter in the previous year, the firm earned ($1.25) EPS. As a group, sell-side analysts anticipate that argenx SE will post 2.78 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.